Huang Ying, Li Wei-Jia, Wei Cai-Xia, Zhou Zhi, Nie Bo
Department of Hematology, The First Affiliated Hospital, Kunming Medicine College, Kunming 650031, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Dec;13(6):959-63.
To investigate the expression of HoxA(10) mRNA in acute leukemia patients and its significance, HoxA(10) level was detected by reverse transcription polymerase chain reaction (RT-PCR) in 50 patients with acute leukemias, 7 healthy volunteers and 3 patients with ITP (idiopathic thrombocytopenic purpura). The regularity of the expression of HoxA(10) gene in acute leukemia and the relationship between HoxA(10) level and the prognosis of leukemia was explored. The results showed that HoxA(10) was expressed in all types of acute myelogenous leukemia; HoxA(10) message was also observed in acute lymphoblastic leukemia patients and part of control groups. 3 normal donors were found not to express HoxA(10). The level of HoxA(10) mRNA of acute myelogenous leukemia patients was significantly higher than that of acute lymphoblastic leukemia patients and controls (P < 0.01). HoxA(10) gene appeared to be more strongly expressed in AML-M(1) and -M(2) subtypes than in AML-M(4) and -M(5) subtypes, and the gene was notable high expressed in acute promyelocytic leukemia. The number of blast and promyeloid cells in the bone marrow was positive related with the level of HoxA (r = 0.635, P < 0.01). The level of HoxA(10) of 9 non-responsive patients was higher than that of 8 remission patients, but there was no significant difference between them (P = 0.258). HoxA(10) was overexpressed in acute myelogenous leukemia. It is concluded that HoxA(10) is a major transcription factor regulating hematopoiesis and a mark to differentiate lymphoid leukemia and myelogenous leukemia, but not a specific gene of cancer. The level of HoxA(10) is related with load of leukemic cells and curative effect, and can affect occurrence and development of leukemia in combination with many cytokines, HoxA(10) may facilitate the leukemia progression with another cofactors.
为研究急性白血病患者中HoxA(10) mRNA的表达及其意义,采用逆转录聚合酶链反应(RT-PCR)检测了50例急性白血病患者、7名健康志愿者及3例特发性血小板减少性紫癜(ITP)患者的HoxA(10)水平。探讨急性白血病中HoxA(10)基因表达的规律以及HoxA(10)水平与白血病预后的关系。结果显示,HoxA(10)在所有类型的急性髓系白血病中均有表达;在急性淋巴细胞白血病患者及部分对照组中也观察到HoxA(10)信息。发现3名正常供者不表达HoxA(10)。急性髓系白血病患者的HoxA(10) mRNA水平显著高于急性淋巴细胞白血病患者及对照组(P < 0.01)。HoxA(10)基因在AML-M(1)和-M(2)亚型中似乎比在AML-M(4)和-M(5)亚型中表达更强,且该基因在急性早幼粒细胞白血病中显著高表达。骨髓中原始细胞和早幼粒细胞的数量与HoxA水平呈正相关(r = 0.635,P < 0.01)。9例未缓解患者的HoxA(10)水平高于8例缓解患者,但两者之间无显著差异(P = 0.258)。HoxA(10)在急性髓系白血病中过表达。结论是,HoxA(10)是调节造血的主要转录因子,是区分淋巴细胞白血病和髓细胞白血病的一个标志,但不是癌症的特异性基因。HoxA(10)水平与白血病细胞负荷及疗效相关,且可与多种细胞因子共同影响白血病的发生发展,HoxA(10)可能与其他辅助因子共同促进白血病进展。